In 2009 Genentech became a member of the Roche Group and the two companies combined their pharmaceutical operations in the US. The San Francisco campus of Genentech serves as headquarters for Roche pharmaceutical operations in the US. Operating as an independent center within Roche is Genentech Research and Early Development.
Genentech was founded by Robert A. Swanson (1947-1999), a venture capitalist, and biochemist Dr. Herbert W. Boyer. Boyer along with Stanley Cohen were pioneers in recombinant DNA technology.
Genetech has drug manufacturing facilities in South San Francisco, Vacaville and Oceanside, California. Genetech focused on large-scale biologics and products for about 30 years. A shift towards developing therapies that target smaller patient populations began around 2013. Genentech has two commercial large volume products, Herceptin and Rituxan, of which they produce more than 2000 kg per year. The company has six products that classify as standard volume products, between 300 kg and 2000 kg per year, as well as three in clinical trials. As of 2019 Genetech had four products considered small volume, less than 300 kg per year, and nine small volume products in the pipeline.
Genentech is developing a virtual reality simulator for eye surgery.
Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk)
Kadcyla® (ado-trastuzumab emtansine)
Rituxan® (rituximab [Oncology])
Rituxan Hycela™ (rituximab and hyaluronidase human)
Immunology and Ophthalmology
Lucentis™ (ranibizumab injection)
Rituxan® (rituximab [Immunology])
Metabolism and Primary Care
Cathflo Activase® (alteplase)
Nutropin AQ® (somatropin (rDNA origin) for injection)
Virology and Specialty Care
CellCept® (mycophenolate mofetil)
Pegasys® (peginterferon alfa-2a)
Pulmozyme® (dornase alfa)
Tamiflu® (oseltamivir phosphate)
Valcyte® (valganciclovir hydrochloride)
Xofluza ™ (baloxavir marboxil)
Boniva Injection® (ibandronate sodium)
Boniva Tablets® (ibandronate sodium)
Invirase® (saquinavir mesylate)
Flatiron Health, Foundation Medicine, and Genentech partner to launch Novel Prospective Lung Cancer Clinical Study.
Alan C Pikna